A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
CoronaVac is a World Health Organization approved inactivated virus vaccination that has been given to over 750 million people in over 40 countries. CoronaVac showed efficacies against symptomatic disease of 50.65 percent, 65.30 percent, and 83.50 percent in phase three randomized clinical trials (R...
Saved in:
| Published in | American journal of respiratory and critical care medicine Vol. 205; no. 7; pp. 844 - 847 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Thoracic Society
01.04.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | CoronaVac is a World Health Organization approved inactivated virus vaccination that has been given to over 750 million people in over 40 countries. CoronaVac showed efficacies against symptomatic disease of 50.65 percent, 65.30 percent, and 83.50 percent in phase three randomized clinical trials (RCTs) in Brazil, Indonesia, and Turkey, respectively. The impact of antibody fading on virus variations has not been studied because these efficacy studies analyzed outcomes within a few months of vaccination. Breakthrough infections have been documented in CoronaVac-vaccinated persons, some of which have resulted in severe disease and death. CoronaVac's immunogenicity is substantially lower than the BNT162b2 mRNA vaccine, according to a recent observational study, and we projected that declining immunity would result in a loss of protection. |
|---|---|
| AbstractList | CoronaVac is a World Health Organization approved inactivated virus vaccination that has been given to over 750 million people in over 40 countries. CoronaVac showed efficacies against symptomatic disease of 50.65 percent, 65.30 percent, and 83.50 percent in phase three randomized clinical trials (RCTs) in Brazil, Indonesia, and Turkey, respectively. The impact of antibody fading on virus variations has not been studied because these efficacy studies analyzed outcomes within a few months of vaccination. Breakthrough infections have been documented in CoronaVac-vaccinated persons, some of which have resulted in severe disease and death. CoronaVac's immunogenicity is substantially lower than the BNT162b2 mRNA vaccine, according to a recent observational study, and we projected that declining immunity would result in a loss of protection. |
| Author | Chen, Chunke Lai, Kiu Cheung Cheng, Samuel M. S. Yiu, Karen Peiris, Malik Sun, Yuanxin Hui, David S. Chan, Tat-On Mok, Chris Ka Pun Ling, Kwun Cheung |
| Author_xml | – sequence: 1 givenname: Chris Ka Pun surname: Mok fullname: Mok, Chris Ka Pun organization: Li Ka Shing Institute of Health SciencesHong Kong Special Administrative Region, People’s Republic of China, The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 2 givenname: Chunke surname: Chen fullname: Chen, Chunke organization: Li Ka Shing Institute of Health SciencesHong Kong Special Administrative Region, People’s Republic of China, The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 3 givenname: Karen surname: Yiu fullname: Yiu, Karen organization: The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 4 givenname: Tat-On surname: Chan fullname: Chan, Tat-On organization: The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 5 givenname: Kiu Cheung surname: Lai fullname: Lai, Kiu Cheung organization: The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 6 givenname: Kwun Cheung surname: Ling fullname: Ling, Kwun Cheung organization: The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 7 givenname: Yuanxin surname: Sun fullname: Sun, Yuanxin organization: Li Ka Shing Institute of Health SciencesHong Kong Special Administrative Region, People’s Republic of China, The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 8 givenname: David S. orcidid: 0000-0003-4382-2445 surname: Hui fullname: Hui, David S. organization: The Chinese University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 9 givenname: Samuel M. S. surname: Cheng fullname: Cheng, Samuel M. S. organization: The University of Hong KongHong Kong Special Administrative Region, People’s Republic of China – sequence: 10 givenname: Malik surname: Peiris fullname: Peiris, Malik organization: The University of Hong KongHong Kong Special Administrative Region, People’s Republic of China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35015969$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1LHTEUhoNY6lf_gAsJdONmbD5nkuXt1dbCRUHG0l3IJBmNzCQ2mUF01Z_eXO-VgovCIecEnvflJO8B2A0xOACOMTrDuGZfkjHjGUEEY1yRmvPVxQ7Yx5zyiskG7ZYZNbRiTP7aAwc5PyCEicDoI9ijHGEua7kP_izgjQ42jv7FWbgcfPBGD7BNvpy32Yc7uIwpBv1TGxgT_HrV4pp0BJa78cFBnaGG7b1PFp7H7KAPcGHnYcpbQk_F98lP97B9iq9IhrH_Z3oEPvR6yO7Tth-C228X7fKyWl1__7FcrCpDGz6tX2FdJ5hBjKEOW4uccYjWtpZCWsJ7wTotqGg07Rk1hnBnNSmFeiwwd_QQnG58H1P8Pbs8qdFn44ZBBxfnrEiNJUESEVHQz-_QhzinULYrFKsbzhmShTrZUnM3Oqsekx91elZvf1sAsQFMijkn1yvjJz35GKak_aAwUusY1TpGtYlRbWIsUvJO-ub-H9Ff2yye6Q |
| CitedBy_id | crossref_primary_10_3389_fimmu_2023_1106837 crossref_primary_10_1093_cid_ciac458 crossref_primary_10_1016_S2666_5247_23_00006_X crossref_primary_10_1001_jamanetworkopen_2022_53301 crossref_primary_10_1080_21645515_2022_2158012 crossref_primary_10_1002_jcla_24731 crossref_primary_10_1164_rccm_202201_0221LE crossref_primary_10_1172_jci_insight_168437 crossref_primary_10_1080_21645515_2023_2165856 crossref_primary_10_3390_vaccines11020216 crossref_primary_10_1016_S1473_3099_22_00640_5 crossref_primary_10_1164_rccm_202201_0077LE crossref_primary_10_3201_eid3001_230414 crossref_primary_10_1080_14760584_2024_2315089 crossref_primary_10_3389_fimmu_2023_1237916 crossref_primary_10_1186_s12929_022_00853_8 crossref_primary_10_1016_j_lanwpc_2022_100586 crossref_primary_10_1016_j_vaccine_2022_05_033 crossref_primary_10_1016_j_lana_2022_100371 crossref_primary_10_1038_s41591_022_01704_7 crossref_primary_10_1016_j_diagmicrobio_2023_116122 crossref_primary_10_1016_j_eclinm_2022_101680 crossref_primary_10_1016_j_idc_2022_11_002 crossref_primary_10_1016_j_imlet_2023_08_002 crossref_primary_10_1097_CM9_0000000000002567 crossref_primary_10_1080_22221751_2022_2149935 crossref_primary_10_2807_1560_7917_ES_2022_27_18_2200178 crossref_primary_10_1001_jamanetworkopen_2022_26046 |
| Cites_doi | 10.1016/j.eclinm.2021.101143 10.1002/jmv.27350 10.1016/S2666-5247(21)00177-4 10.1016/j.eclinm.2021.101174 10.1038/s41591-021-01377-8 |
| ContentType | Journal Article |
| Copyright | Copyright American Thoracic Society Apr 1, 2022 |
| Copyright_xml | – notice: Copyright American Thoracic Society Apr 1, 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
| DOI | 10.1164/rccm.202111-2655LE |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1535-4970 |
| EndPage | 847 |
| ExternalDocumentID | 35015969 10_1164_rccm_202111_2655LE |
| Genre | Letter Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: U01 AI151810 |
| GroupedDBID | --- -~X .55 0R~ 23M 2WC 34G 39C 53G 5GY 5RE 7RV 7X7 8C1 8FW 8R4 8R5 AAQQT AAWTL AAYXX ABJNI ABOCM ABPMR ACGFO ACGFS ADBBV AENEX AFCHL AFUWQ AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BPHCQ C45 CITATION CS3 DIK E3Z EBS EJD EMOBN EX3 F5P FRP GX1 H13 HZ~ IH2 J5H KQ8 L7B M5~ O9- OBH OFXIZ OGEVE OK1 OVD OVIDX P2P PCD PQQKQ Q2X RWL SJN TAE TEORI THO TR2 W8F WH7 WOQ WOW X7M YJK ~02 3V. CGR CUY CVF ECM EIF NPM RPM K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c375t-449deb84c0440b1dd0ece036d6989d25f84ba8387a3f43cc25eda2da20f1815e3 |
| ISSN | 1073-449X 1535-4970 |
| IngestDate | Thu Jul 10 17:39:53 EDT 2025 Sun Jun 29 12:15:45 EDT 2025 Thu Jan 02 22:53:17 EST 2025 Tue Jul 01 02:01:19 EDT 2025 Thu Apr 24 23:03:22 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c375t-449deb84c0440b1dd0ece036d6989d25f84ba8387a3f43cc25eda2da20f1815e3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Correspondence-1 content type line 23 ObjectType-Undefined-2 ObjectType-Article-3 |
| ORCID | 0000-0003-4382-2445 |
| OpenAccessLink | https://www.atsjournals.org/doi/pdf/10.1164/rccm.202111-2655LE |
| PMID | 35015969 |
| PQID | 2646755409 |
| PQPubID | 40575 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_2619209028 proquest_journals_2646755409 pubmed_primary_35015969 crossref_citationtrail_10_1164_rccm_202111_2655LE crossref_primary_10_1164_rccm_202111_2655LE |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-01 20220401 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York |
| PublicationTitle | American journal of respiratory and critical care medicine |
| PublicationTitleAlternate | Am J Respir Crit Care Med |
| PublicationYear | 2022 |
| Publisher | American Thoracic Society |
| Publisher_xml | – name: American Thoracic Society |
| References | bib7 bib8 bib5 Mok CKP (bib3) bib4 Pietsch B (bib6) 2021 bib10 35561336 - Am J Respir Crit Care Med. 2022 Aug 1;206(3):360-361 35561327 - Am J Respir Crit Care Med. 2022 Aug 1;206(3):361-362 |
| References_xml | – ident: bib7 doi: 10.1016/j.eclinm.2021.101143 – ident: bib10 doi: 10.1002/jmv.27350 – ident: bib3 publication-title: Respirology – year: 2021 ident: bib6 publication-title: The Washington Post – ident: bib8 doi: 10.1016/S2666-5247(21)00177-4 – ident: bib5 doi: 10.1016/j.eclinm.2021.101174 – ident: bib4 doi: 10.1038/s41591-021-01377-8 – reference: 35561327 - Am J Respir Crit Care Med. 2022 Aug 1;206(3):361-362 – reference: 35561336 - Am J Respir Crit Care Med. 2022 Aug 1;206(3):360-361 |
| SSID | ssj0012810 |
| Score | 2.5233746 |
| Snippet | CoronaVac is a World Health Organization approved inactivated virus vaccination that has been given to over 750 million people in over 40 countries. CoronaVac... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 844 |
| SubjectTerms | Adult BNT162 Vaccine Clinical trials COVID-19 Vaccines Humans Immunization Older people Vaccines |
| Title | A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35015969 https://www.proquest.com/docview/2646755409 https://www.proquest.com/docview/2619209028 |
| Volume | 205 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7qCsu-iHerq4zgW4kmk5lp8liLuihdRVpZn8IkM8GybrKkCcI--W_8m54zyaRx64oKIaSZkwn0-zI5J-dGyDPmqyDMMualMgYDJdfMi1Wae6GOTBjnUimGycmLY3m04m9PxMlo9GMQtdTU6fPs4rd5Jf-DKpwDXDFL9h-Q7SeFE3AM-MIeEIb9X2E8m3xUhS7P1hf4ndblOC5tI45V59GvQNX-pDKMO395vAwkS9kEfqM_HXvMKOzcWWlQpDe2fMgM63FsOglVu-D05bfSitjAj37SoWbbu34GtSiqgR_f5s-5vgo23uyyW39RnvblDibv1ORD0xN33uWQzL80xWl_wed1s5PPhtkSloOq9t4Xw28aYA5vQ2GMW4cFNr_zhws188WAkdPBshu1NSR3XweSA4ZVlmHNATB1A49JIdoKJwN-nJ9ZgqCPVcRt55hLRbjd0DVynYE9gq0y3pz0sUTojfRdRpbkL3ZveED23RS_KkBXWDVWu1neJDc6s4TOWo7dIiNT3Cb7iw6hO-T7jG6pRh3VqKUatVSjPStoWVFHNdpRjaoNVdRSjSKP6LqgLdXolmoUqUaBalZkQ8t8O-ldsnr9ajk_8rrmHV4WTkXtcR5rk0Y8w57maaC1b7A1ndTYsVQzkUc8VVEYTVWYc1wthNGKwebnoHQKE94je0VZmAeEskgoA4Y8vLgVD0CB0hrkwXCRMuJRHIxJ4P7RJOsq22ODla-JtXAlTxCQpAUkaQEZk0l_zXlb1-WP0ocOqKR7ijYwBEoGaON-PCZP-2FYndHlpgpTNigDFhSGPkdjcr8FuL-dI8TDK0cekYPt03FI9uqqMY9BB67TJ5Z_PwGUmq4k |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Randomized+Clinical+Trial+Using+CoronaVac+or+BNT162b2+Vaccine+as+a+Third+Dose+in+Adults+Vaccinated+with+Two+Doses+of+CoronaVac&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=Mok%2C+Chris+Ka+Pun&rft.au=Chen%2C+Chunke&rft.au=Yiu%2C+Karen&rft.au=Chan%2C+Tat-On&rft.date=2022-04-01&rft.eissn=1535-4970&rft.volume=205&rft.issue=7&rft.spage=844&rft_id=info:doi/10.1164%2Frccm.202111-2655LE&rft_id=info%3Apmid%2F35015969&rft.externalDocID=35015969 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1073-449X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1073-449X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1073-449X&client=summon |